OPTIMAL VS NORMAL LAB REFERENCE RANGES: THE NUMBERS YOUR DOCTOR USES VS THE NUMBERS THAT MATTER FOR LONGEVITY

When a blood test result comes back and your doctor tells you everything is normal, what they are actually saying is: your result falls within the middle 95% of values from the reference population this lab used to calibrate its assay. That population is not a group of elite athletes or metabolically optimal individuals. It is drawn from the same pool of people who visit clinics and hospitals — a population in which, in the United States alone, 88% are metabolically unhealthy by comprehensive criteria, over 50% are pre-diabetic or diabetic, and rates of obesity, cardiovascular disease, and inflammatory conditions have risen steadily for decades.

The implication is uncomfortable but important: "normal" reference ranges are calibrated to a sick population. A result that falls neatly inside the reference range is not a statement of health — it is a statement that you are similar to the average of the people who generated that range. For many of the most predictive biomarkers, the clinically meaningful threshold for disease risk lies well inside the conventional "normal" zone. Understanding the distinction between statistical normality and biological optimality is arguably the single most important interpretive skill in reading a blood test.

How Reference Ranges Are Constructed — and Why That Matters

Standard laboratory reference ranges are built using a method called the reference interval — typically the 2.5th to 97.5th percentile of a reference cohort. By definition, 5% of healthy individuals will fall outside the reference range by chance alone. When you run 20 tests on a single blood draw, the probability that at least one result will be outside the reference range by statistical chance exceeds 60% — this is a fundamental property of the method, not a sign of pathology.

Reference cohorts are supposed to be drawn from "apparently healthy" individuals, but the criteria for that designation vary between labs and have not kept pace with the growing prevalence of subclinical metabolic disease. Fasting glucose of 99 mg/dL qualifies as "healthy" by most labs' criteria, meaning the reference cohort includes many individuals with insulin resistance, metabolic syndrome, and early-stage type 2 diabetes. This explains why the upper end of the glucose reference range (100 mg/dL, or in some labs 110 mg/dL) is itself a metabolic disease threshold.

Optimal ranges, by contrast, are derived from prospective outcome studies and dose-response analyses: researchers measure biomarker levels in large populations and then track who develops disease, cognitive decline, or premature mortality over 10-20 years. They then identify the biomarker thresholds that minimise adverse outcomes — thresholds that often sit substantially below the conventional reference range upper limits. This is the foundation of functional and longevity medicine's different approach to interpreting labs.

Fasting Glucose and HbA1c: The Most Important Examples

Fasting glucose is the single most instructive example of the optimal-versus-normal gap. Conventional reference ranges flag fasting glucose above 100 mg/dL as "impaired fasting glucose" and above 126 mg/dL as diagnostic of diabetes. Within the "normal" range — 70-99 mg/dL — outcome research tells a different story.

A landmark analysis from the San Antonio Heart Study and other prospective cohorts found that cardiovascular disease risk begins rising meaningfully at fasting glucose above 85 mg/dL — a level that is unambiguously within the "normal" reference range. The lowest risk population for both cardiovascular events and progression to type 2 diabetes has consistently fasting glucose in the 70-85 mg/dL range. The functional medicine optimal target is therefore 70-85 mg/dL, not "below 100 mg/dL."

HbA1c tells the same story. Conventional ranges flag HbA1c above 5.7% as "pre-diabetes" and above 6.5% as diabetes. But outcome data show that HbA1c above 5.4-5.5% is associated with meaningfully elevated cardiovascular risk, and the lowest all-cause mortality in non-diabetic populations is seen with HbA1c between 4.8% and 5.4%. The functional optimal is below 5.5%, with 5.0-5.2% being genuinely low-risk. Someone with an HbA1c of 5.6% will be told their result is "borderline" — but outcome data suggest they are already accumulating glycation-related vascular damage.

Fasting insulin is perhaps the most revealing metabolic marker that virtually no standard panel includes. Reference ranges for fasting insulin span roughly 2-25 μIU/mL. Functional medicine targets fasting insulin below 5 μIU/mL, with levels above 10 μIU/mL (well within the conventional "normal" range) indicating significant insulin resistance. HOMA-IR (homeostatic model assessment for insulin resistance) is calculated as fasting glucose × fasting insulin / 405; a result above 1.5 indicates emerging insulin resistance, above 2.0 is moderate, above 3.0 is significant — all of which can occur with both glucose and insulin individually reading as "normal."

Lipids: Why LDL-C Is the Wrong Number to Focus On

Standard lipid panels report total cholesterol, LDL-C (calculated LDL cholesterol), HDL-C, and triglycerides. LDL-C is the number most physicians and patients focus on, but it is a calculated estimate derived from the Friedewald equation — not a direct measurement. More importantly, LDL-C measures the total mass of cholesterol carried in LDL particles, not the number of those particles. It is the number of LDL particles (LDL-P, measured by NMR spectroscopy) or their protein component (ApoB, measured directly) that actually determines cardiovascular risk.

The discordance between LDL-C and LDL-P occurs specifically because small, dense LDL particles carry less cholesterol per particle. A person with elevated LDL-P and small LDL particles may have a relatively normal LDL-C — and vice versa. Studies consistently show that LDL-P is a better predictor of cardiovascular events than LDL-C when the two are discordant.

Conventional thresholds flag LDL-C above 130 mg/dL as "borderline high" and above 160 mg/dL as "high." Longevity-focused practitioners target ApoB below 90 mg/dL (or below 70 mg/dL in high-risk individuals), LDL-P below 1000 nmol/L, and total cholesterol-to-HDL ratio below 3.5. Triglycerides below 100 mg/dL (optimal) versus the conventional "normal" threshold of 150 mg/dL represent another important gap — elevated triglycerides in the 100-150 mg/dL range predict insulin resistance and VLDL overproduction that standard reference ranges would classify as unremarkable.

Vitamin D: A Reference Range Calibrated to Prevent Rickets, Not Optimise Health

The vitamin D story is among the most illustrative examples of how reference ranges can systematically undershoot biological optimality. Most labs flag 25-hydroxyvitamin D (25-OH-D) as "deficient" below 20 ng/mL and "insufficient" at 20-30 ng/mL, with "sufficient" beginning at 30 ng/mL. These thresholds were established primarily based on the level required to prevent rickets and osteomalacia — severe deficiency diseases. They say nothing about the vitamin D levels associated with optimal immune function, cancer risk reduction, cardiovascular protection, or cognitive health.

Outcome data from prospective cohort studies and Mendelian randomisation analyses consistently show that the lowest rates of multiple sclerosis, colorectal cancer, cardiovascular disease, type 2 diabetes, and all-cause mortality are observed at 25-OH-D levels of 50-80 ng/mL. The Grassroots Health global epidemiology data (n>10,000 subjects followed over 10+ years) show a disease incidence nadir at approximately 60 ng/mL. Most adults in northern latitudes have 25-OH-D levels of 15-35 ng/mL — technically "sufficient" or at worst "insufficient" by conventional standards, but substantially below the functional optimal.

Ferritin: Normal Can Mean Either Deficiency or Excess

Ferritin is the primary intracellular iron storage protein, and its serum concentration is used as a surrogate for total body iron stores. The conventional reference range for ferritin is typically 12-300 ng/mL for men and 12-150 ng/mL for women — an extraordinarily wide range that obscures clinically meaningful distinctions at both ends.

At the low end, ferritin below 30 ng/mL is associated with iron-deficiency symptoms — fatigue, hair loss, impaired exercise tolerance, restless legs syndrome — even when haemoglobin remains normal. Many labs will flag ferritin of 15 ng/mL as "low-normal," but at this level cellular iron availability for mitochondrial energy production is already compromised. The functional optimal for ferritin in pre-menopausal women is 50-100 ng/mL; in men, 70-150 ng/mL.

At the high end, ferritin above 200 ng/mL in women or above 300 ng/mL in men is associated with increased cardiovascular disease risk, non-alcoholic fatty liver disease, insulin resistance, and — at higher levels — hereditary haemochromatosis if untreated. Ferritin is also an acute-phase reactant, meaning it rises with inflammation independently of iron status. A ferritin of 250 ng/mL might represent iron overload, inflammation (in which case actual iron stores may be normal), or both — interpretation requires a full iron panel including transferrin saturation, serum iron, and TIBC.

TSH and Thyroid Markers: The Widest Clinical Gap

The TSH reference range is one of the most contested in clinical medicine. Most labs use 0.4-4.5 mIU/L or 0.35-5.5 mIU/L — ranges that were established by measuring TSH in a reference population that was not systematically screened to exclude those with early thyroid disease. Multiple endocrinological societies have proposed narrowing the upper limit to 2.5-3.0 mIU/L, without consensus.

Outcome-based research supports a genuinely optimal TSH of 1.0-2.0 mIU/L. Population studies show that TSH progressively above 2.0-2.5 mIU/L is associated with rising LDL cholesterol, increasing cardiovascular risk, and worsening metabolic markers — all before reaching the conventional "abnormal" threshold of 4.5 mIU/L. In older adults, a TSH consistently above 3.5 mIU/L is associated with higher rates of atrial fibrillation when treated — which has created an evidence base for being more conservative with TSH in certain populations.

The practical implication is that a TSH of 3.8 mIU/L — completely "normal" by conventional standards — in a symptomatic patient with fatigue, cold intolerance, and elevated cholesterol warrants investigation with Free T4, Free T3, and thyroid antibodies, rather than reassurance that the thyroid is "fine." The reference range normalises a level that population data associates with suboptimal metabolic function.

How to Apply Optimal Ranges in Practice

Using optimal ranges rather than reference ranges changes how you interact with blood test results. Instead of asking "is my result flagged as abnormal?", you ask "where does my result sit relative to the evidence-based optimum for that marker?" This requires knowing the relevant optimal targets — a growing body of literature from longevity medicine, preventive cardiology, and functional medicine provides these.

A summary of key optimal targets: fasting glucose 70-85 mg/dL; HbA1c below 5.5%; fasting insulin below 5 μIU/mL; HOMA-IR below 1.0; LDL-C below 100 mg/dL (or ApoB below 80 mg/dL); triglycerides below 100 mg/dL; HDL above 60 mg/dL; hs-CRP below 1.0 mg/L; homocysteine below 8 μmol/L; 25-OH vitamin D at 50-80 ng/mL; ferritin 70-150 ng/mL (men), 50-100 ng/mL (women); TSH 1.0-2.0 mIU/L; Free T3 in the upper third of the reference range; and uric acid below 5.5 mg/dL (recent data link uric acid above 5.5 mg/dL with increased cardiovascular risk, metabolic syndrome, and gout precursor states, well below the conventional "abnormal" threshold of 7.0 mg/dL in men).

The flag system on standard lab reports — the H and L annotations that indicate values outside the reference range — is calibrated to prevent diagnostic miss of serious acute pathology, not to guide proactive health optimisation. For longevity and disease prevention, the flag system is the wrong tool. What you need is a framework for interpreting absolute values in the context of outcome data — which is precisely what functional and precision medicine practitioners spend most of their clinical energy doing.